Ophthalmology
The Ophthalmology Group is primarily focused on age-related macular degeneration (AMD). The approach is to better understand the role of the complement system in the onset and progression of the disease with the ultimate goal of correcting the aberrant complement cascade to prevent the disease (through the inhibition of the complement system). The group also develops compounds for topical delivery to treat retinal disease, inlcuding AMD.
The Ophthalmology Group concentrates on the treatment and prevention of age-related macular degeneration and the treatment of glaucoma.
Clinical trials
Novartis clinical trials are designed to find better ways to treat or prevent diseases.
Products in development
Discovery Sciences
Applying key expertise and technologies across diseases that share similar mechanisms...